Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa

AIMS: To report the safety and efficacy of intravitreal aflibercept (Eylea) (ivA) for retinitis pigmentosa-associated cystoid macular oedema (RP-CMO) at 12 months via mean central macular thickness (CMT) and reported adverse events. METHODS: A prospective, exploratory, phase II, non-randomised, sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Strong, Stacey A, Peto, Tunde, Bunce, Catey, Xing, Wen, Georgiou, Michalis, Esposti, Simona Degli, Kalitzeos, Angelos, Webster, Andrew, Michaelides, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577098/
https://www.ncbi.nlm.nih.gov/pubmed/32041720
http://dx.doi.org/10.1136/bjophthalmol-2019-315152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577098/
https://www.ncbi.nlm.nih.gov/pubmed/32041720
http://dx.doi.org/10.1136/bjophthalmol-2019-315152

Ejemplares similares